Vaccine Info

Trumenba Meningitis B Vaccine

Trumenba is a sterile suspension composed of two recombinant lipidated factor H binding protein (fHBP) variants from N. meningitidis serogroup B, one from fHBP subfamily A and one from subfamily B (A05 and B01, respectively).

Trumenba is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B.

Trumenba is intended for intramuscular injection administered as a three-dose series in individuals 10-25 years of age following a 0-, 2-, and 6-month schedule.

On October 29, 2014, the U.S. Food and Drug Administration sent an approval letter authorizing the introduction or delivery of Trumenba into interstate commerce.

 

 

Updated
July 2nd, 2019